Moderna Stock News

It''s based on older technology than Pfizer or Moderna

PARIS: Giving a full dose of Moderna''s COVID-19 vaccine as a booster shot provides more antibody protection against the Omicron variant than currently authorised half-strength injections, the company said on Monday (Dec 20). The lab study measured the levels of Omicron-neutralising antibodies in

Moderna shares surged higher in pre-market trading after the drugmaker said booster shots of its coronavirus vaccine induced a big jump in antibodies that can fight against the Omicron variant.

The post Moderna says booster of its Covid vaccine increases protection appeared on BitcoinEthereumNews.com . Empty bottles of Moderna Covid-19 vaccine are pictured in a vaccination center in Garlan, western France, on December 13, 2021. FRED TANNEAU | AFP | Getty Images Moderna announced Monday

Moderna shared new data which shows that a 50 microgram dose of its booster vaccine increases the level of neutralizing antibodies 37-fold.

Modern described the findings as reassuring, but said it will also continue to develop an omicron-specific booster candidate.

(RTTNews) - Moderna, Inc. (MRNA) reported preliminary neutralizing antibody data against the Omicron variant following booster candidates at 50 g and 100 g dose levels. The currently authorized 50 g booster of mRNA-1273 increased neutralizing antibody levels against Omicron approximately 37-fold compared to pre-boost levels. A 100 g dose of

The company still plans to develop a vaccine specifically to protect against Omicron, which it hopes to advance into clinical trials early next year.

A THIRD dose of the Moderna vaccine offered a significant antibody response in the immune system in a "reassuring" trial.

The vaccine maker said the decision to focus on the current vaccine, mRNA-1273, was driven in part by how quickly the recently discovered variant is spreading

I expect a tidal wave of investing cash to move to this area of biotech due to Pfizer and Modernas success, and this part of the biotech sphere will benefit in the same way Tesla did. The post Investing in an Unreal 2022 appeared first on Money Morning Australia .

Pfizer Pushes Third Vaccine Dose For Kids 5 And Under As Pfizer and Moderna fight to get their COVID jabs approved for children under the age of 5, Pfizer revealed on Friday that it''s changing its approach by testing three vaccine doses in babies and preschoolers after discovering that two doses simply doesn''t provide enough protection. According to the AP , Pfizer announced the change after a preliminary analysis found 2- to 4-year-olds didnt have as strong an immune response as expected to the very low-dose shots the company is testing in the youngest children. All of this seems funny to us off the bat because it was our understanding that youngsters had natural immunity to the virus barring some immunodeficiency issue. Pfizer said it had expected data on how well the vaccines were working in children under 5 by year''s end. Now, nobody knows how long that might take as the company tries out different strategy. But one thing''s for sure: Pfizer is about to be selling a lot more vaccines.

Axiom Investors Bradley Amoils employs a clever process that has allowed the fund manager to find some early gems.